Logo India Globalization Capital, Inc. - IGC 0.32 USD

EPS
-0.20
P/B
3.36
ROE
-126.20
Beta
1.29
Target Price
3.75 USD

0.323 USD

0.323 USD

Daily: +4.23%
Key Metrics

EPS: -0.20

Book Value: 0.11

Price to Book: 3.36

Debt/Equity: 4.29

% Insiders: 7.918%

Growth

Revenue Growth: -0.51%

Estimates

Forward P/E: -3.08

Forward EPS: -0.10

Target Mean Price: 3.75

 Logo About India Globalization Capital, Inc. - (IGC)

Country: United States

Sector: Industrials

Website: http://www.igcinc.us

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Exchange Ticker
ASE (United States) IGC
FRA (Germany) IGS1.F

Dividends

Historical Split Corporate Actions

Split Date Split Ratio to 1
April 19, 2013 0.10
Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion